Anti-S100A4 antibody
Specifications
| Product Cat#: | AB-06-3950 | |
| Product type: | Primary antibody | |
| Antigen: | S100A4 | |
| Immunogen: | Recombinant protein | |
| Species immunized: | Rabbit | |
| Isotype: | IgG | |
| Applications: | Western Blot (1:100-1:1000); Immunohistochemistry (1:100-1:200); Immunocytochemistry (1:100-1:200)/Immunofluorescence; Flow Cytometry (1:100-1:200) | |
| Reactivity: | Human, Mouse, Rat | |
| Clonality (clone number): | Monoclonal (SD200-08) | |
| Form: | Liquid | |
| Buffer: | 1*TBS (pH7.4), 1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. | |
| Concentration: | 1 mg/ml | |
| Purity: | Protein A affinity purified | |
| Storage: | Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. | |
| Alternative names: | 18A2 antibody | |
| 42A antibody | ||
| calcium Placental protein antibody | ||
| Calvasculin antibody | ||
| CAPL antibody | ||
| Fibroblast specific protein 1 (FSP1) antibody | ||
| Fibroblast specific protein 1 antibody | ||
| Fibroblast specific protein antibody | ||
| FSP1 antibody | ||
| Leukemia multidrug resistance associated protein antibody | ||
| Malignant transformation suppression 1 (MTS1) antibody | ||
| Malignant transformation suppression 1 antibody | ||
| Metastasin antibody | ||
| MTS1 antibody | ||
| OTTHUMP00000015467 antibody | ||
| OTTHUMP00000015468 antibody | ||
| P9KA antibody | ||
| PEL98 antibody | ||
| Placental calcium-binding protein antibody | ||
| Protein Mts1 antibody | ||
| Protein S100 A4 antibody | ||
| Protein S100-A4 antibody | ||
| S100 calcium binding protein A4 (calcium protein, calvasculin, metastasin, murine | placental homolog) antibody | |
| S100 calcium binding protein A4 antibody | ||
| S100 calcium-binding protein A4 antibody |
Target information
The Mts1 gene encodes a small acidic Ca2+-binding protein, Mts1 (also designated S100A4, calvasculin or metastasin). Mts1 belongs to the S100 family of small Ca2+-binding proteins and is expressed in a cell-specific manner. Mts1 protein is involved in tumor progression and metastasis, and also has a significant stimulatory effect on angiogenesis. The level of Mts1 protein in serum increases with aging, suggesting that Mts1 may play a role in the ind-uction of tumor progression via stimulation of angiogenesis. In addition, Mts1 cooperates with p53 in apoptosis induction by binding to the C-term-inal regulatory domain of p53 to inhibit the DNA binding activity of p53. The ability of Mts1 to enhance p53-dependent apoptosis may accelerate the loss of p53 function in tumors. Thus, Mts1 can contribute to the development of a more aggressive phenotype during tumor progression.
Provider
Erpantech Laboratory
